In clinical treatment, drug resistance remains one of the most serious challenges to achieving durable responses in cancer therapy. Even the most promising drugs can lose effectiveness as tumors adapt, driven by mechanisms such as genetic mutations, pathway reprogramming, and tumor microenvironmental changes. To outpace cancer’s resilience, researchers need reliable preclinical models that replicate these resistance pathways.
This expert led talk highlights how Crown Bioscience develops drug resistant cell line derived xenograft (CDX) models, offering a powerful platform to study mechanisms of resistance and accelerate next-generation therapeutic development.
Watch the on-demand webinar to gain insider access to strategies and data that can support your oncology pipeline, from validating resistance biology to exploring new therapeutic combinations.